Valuation: Pelthos Therapeutics Inc.

Market Cap 102M 87.39M 81.54M 74.82M 141M 9.77B 143M 967M 377M 4.89B 383M 375M 16.2B P/E 2026 *
-1.56x
P/E 2027 * -9.48x
Enterprise Value 102M 87.39M 81.54M 74.82M 141M 9.77B 143M 967M 377M 4.89B 383M 375M 16.2B EV / Sales 2026 *
1.6x
EV / Sales 2027 * 0.91x
Free-Float
51.18%
Yield 2026 *
-
Yield 2027 * -
1 day+3.25%
1 week-7.91%
Current month-6.98%
1 month-2.20%
3 months-1.66%
6 months+14.72%
Current year-14.00%
1 week 25.69
Extreme 25.69
28.14
1 month 25.33
Extreme 25.33
29.8
Current year 18.19
Extreme 18.19
30.99
1 year 18.19
Extreme 18.19
37.5
3 years 4.5
Extreme 4.5
60
5 years 4.5
Extreme 4.5
60
10 years 4.5
Extreme 4.5
60
Date Insider Type Main position Quantity % Market Cap.
2/7/26 Sell

Director

-558 0.0161%
2/7/26 Sell

Director

-786 0.0226%
2/7/26 Sell

Chairman

-797 0.0229%
Change 5-day change 1-year change 3-year change Capi.($)
+3.25%-7.91%+24.52% - 102M
-2.81%+2.93%+76.40%+127.73% 1,109B
-2.21%+2.02%+49.50%+55.01% 644B
-1.56%+4.39%+25.19%+74.39% 463B
-1.41%+3.13%+39.50%+44.00% 371B
-1.09%+1.98%+21.39%+38.73% 301B
-0.60%+4.72%-0.40%+12.43% 256B
-1.95%+3.80%+46.31%+65.66% 234B
-0.41%+0.05%-17.20%-53.24% 205B
-2.82%+3.84%+20.81%+89.04% 178B
Average -0.19%+1.91%+28.60%+50.42% 376.12B
Weighted average by Cap. -0.26%+3.26%+42.63%+69.94%

Financials

2026 *2027 *
Net sales 63.75M 54.58M 50.92M 46.73M 87.81M 6.1B 89.53M 604M 236M 3.06B 239M 234M 10.12B 112M 96.08M 89.64M 82.26M 155M 10.74B 158M 1.06B 415M 5.38B 421M 412M 17.82B
Net income -62.08M -53.15M -49.59M -45.51M -85.51M -5.94B -87.19M -588M -229M -2.98B -233M -228M -9.86B -24.96M -21.37M -19.94M -18.29M -34.37M -2.39B -35.05M -237M -92.19M -1.2B -93.7M -91.67M -3.96B
Net Debt - -
Logo Pelthos Therapeutics Inc.
Pelthos Therapeutics Inc. is a biopharmaceutical company focused on commercializing therapeutic products for unmet patient needs. The Company's lead product, ZELSUVMI (berdazimer) topical gel, 10.3%, is used in the treatment of molluscum contagiosum infections (molluscum) in adults and pediatric patients one year of age and older. In addition to ZELSUVMI, the Company has a pipeline of product candidates that utilize its proprietary nitric oxide-based technology platform, NITRICIL. The Company’s product Xepi is a quinolone antimicrobial indicated for the topical treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients two months of age and older. Its NaV 1.7 is a clinical-stage assets which selectively target the sodium ion-channel. The Company also Xeglyze, which is a is a pediculicide indicated for the topical treatment of head lice infestation in patients six months of age and older.
Employees
92
Date Price Change Volume
20/08/26 USD 26.66 +3.25% 24,235
19/08/26 USD 25.82 -1.11% 17,786
18/08/26 USD 26.11 +0.81% 21,167
17/08/26 USD 25.90 -5.82% 29,255
14/08/26 USD 27.50 -5.01% 23,287
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
26.66USD
Average target price
53.14USD
Spread / Average Target
+99.34%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PTHS Stock